National Institute for Health and Care Excellence

Draft for consultation

Neonatal Parenteral Nutrition

Supplementary material D - Health economic literature

NICE guideline tbc

Supplementary material D

September 2019

Draft for Consultation

Supplementary materials were developed by the National Guideline Alliance which is part of the Royal College of Obstetricians and Gynaecologists



Disclaimer

The recommendations in this guideline represent the view of NICE, arrived at after careful consideration of the evidence available. When exercising their judgement, professionals are expected to take this guideline fully into account, alongside the individual needs, preferences and values of their patients or service users. The recommendations in this guideline are not mandatory and the guideline does not override the responsibility of healthcare professionals to make decisions appropriate to the circumstances of the individual patient, in consultation with the patient and/or their carer or guardian.

Local commissioners and/or providers have a responsibility to enable the guideline to be applied when individual health professionals and their patients or service users wish to use it. They should do so in the context of local and national priorities for funding and developing services, and in light of their duties to have due regard to the need to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Nothing in this guideline should be interpreted in a way that would be inconsistent with compliance with those duties.

NICE guidelines cover health and care in England. Decisions on how they apply in other UK countries are made by ministers in the <u>Welsh Government</u>, <u>Scottish Government</u>, and <u>Northern Ireland Executive</u>. All NICE guidance is subject to regular review and may be updated or withdrawn.

Copyright

© NICE, 2019. All rights reserved. Subject to Notice of Rights.

ISBN:

DRAFT FOR CONSULTATION Supplementary material D - Health economic literature

Contents

| Economic literature search strategies | 5 |
|---|---|
| Databases: Medline; Medline EPub Ahead of Print; and Medline In-Process & Other Non-Indexed Citations | 5 |
| Databases: Embase; and Embase Classic | 6 |
| Database: Cochrane Central Register of Controlled Trials | 7 |
| Databases: Health Technology Assessment; and NHS Economic Evaluation Database | 8 |
| Economic study selection | 9 |

Economic literature search strategies

Databases: Medline; Medline EPub Ahead of Print; and Medline In-Process & Other Non-Indexed Citations

| Otne | r Non-Indexed Citations | | | | |
|------|---|--|--|--|--|
| # | Searches | | | | |
| 1 | ECONOMICS/ | | | | |
| 2 | VALUE OF LIFE/ | | | | |
| 3 | exp "COSTS AND COST ANALYSIS"/ | | | | |
| | | | | | |
| 4 | exp ECONOMICS, HOSPITAL/ | | | | |
| 5 | exp ECONOMICS, MEDICAL/ | | | | |
| 6 | exp RESOURCE ALLOCATION/ | | | | |
| 7 | ECONOMICS, NURSING/ | | | | |
| 8 | ECONOMICS, PHARMACEUTICAL/ | | | | |
| 9 | exp "FEES AND CHARGES"/ | | | | |
| 10 | exp BUDGETS/ | | | | |
| 11 | budget*.ti,ab. | | | | |
| 12 | cost*.ti,ab. | | | | |
| | | | | | |
| 13 | (economic* or pharmaco?economic*).ti,ab. | | | | |
| 14 | (price* or pricing*).ti,ab. | | | | |
| 15 | (financ* or fee or fees or expenditure* or saving*).ti,ab. | | | | |
| 16 | (value adj2 (money or monetary)).ti,ab. | | | | |
| 17 | resourc* allocat*.ti,ab. | | | | |
| 18 | (fund or funds or funding* or funded).ti,ab. | | | | |
| 19 | (ration or rations or rationing* or rationed).ti.ab. | | | | |
| 20 | ec.fs. | | | | |
| 21 | or/1-20 | | | | |
| | | | | | |
| 22 | INFANT, NEWBORN/ | | | | |
| 23 | (neonat\$ or newborn\$ or new-born\$ or baby or babies).ti,ab. | | | | |
| 24 | PREMATURE BIRTH/ | | | | |
| 25 | ((preterm\$ or pre-term\$ or pre-matur\$ or pre-matur\$) adj5 (birth? or born)).ab,ti. | | | | |
| 26 | exp INFANT, PREMATURE/ | | | | |
| 27 | ((preterm\$ or pre-term\$ or pre-matur\$ or pre-matur\$) adj5 infan\$).ti,ab. | | | | |
| 28 | (pre#mie? or premies).ti,ab. | | | | |
| 29 | | | | | |
| | exp INFANT, LOW BIRTH WEIGHT/ | | | | |
| 30 | (low adj3 birth adj3 weigh\$ adj5 infan\$).ti,ab. | | | | |
| 31 | ((LBW or VLBW) adj5 infan\$).ti,ab. | | | | |
| 32 | INTENSIVE CARE, NEONATAL/ | | | | |
| 33 | INTENSIVE CARE UNITS, NEONATAL/ | | | | |
| 34 | NICU?.ti,ab. | | | | |
| 35 | or/22-34 | | | | |
| 36 | PARENTERAL NUTRITION/ | | | | |
| 37 | PARENTERAL NUTRITION, TOTAL/ | | | | |
| 38 | PARENTERAL NUTRITION, TOTAL/ PARENTERAL NUTRITION SOLUTIONS/ | | | | |
| 39 | ADMINISTRATION, INTRAVENOUS/ | | | | |
| | · | | | | |
| 40 | INFUSIONS, INTRAVENOUS/ | | | | |
| 41 | CATHETERIZATION, CENTRAL VENOUS/ | | | | |
| 42 | exp CATHETERIZATION, PERIPHERAL/ | | | | |
| 43 | (parenteral\$ or intravenous\$ or intra-venous\$ or IV or venous\$ or infusion?).ti,ab. | | | | |
| 44 | ((peripheral\$ or central\$) adj3 (line? or catheter\$)).ti,ab. | | | | |
| 45 | drip?.ti,ab. | | | | |
| 46 | 0r/36-45 | | | | |
| 47 | 35 and 46 | | | | |
| 48 | limit 47 to english language | | | | |
| | | | | | |
| 49 | LETTER/ | | | | |
| 50 | EDITORIAL/ | | | | |
| 51 | NEWS/ | | | | |
| 52 | exp HISTORICAL ARTICLE/ | | | | |
| 53 | ANECDOTES AS TOPIC/ | | | | |
| 54 | COMMENT/ | | | | |
| 55 | CASE REPORT/ | | | | |
| 56 | (letter or comment*).ti. | | | | |
| 57 | or/49-56 | | | | |
| 37 | | | | | |
| N I | notal parantaral putrition: Supplementary motorial. Health accommissity return DDAET | | | | |

Neonatal parenteral nutrition: Supplementary material – Health economic literature DRAFT (September 2019)

| # | Searches |
|----|--|
| 58 | RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab. |
| 59 | 57 not 58 |
| 60 | ANIMALS/ not HUMANS/ |
| 61 | exp ANIMALS, LABORATORY/ |
| 62 | exp ANIMAL EXPERIMENTATION/ |
| 63 | exp MODELS, ANIMAL/ |
| 64 | exp RODENTIA/ |
| 65 | (rat or rats or mouse or mice).ti. |
| 66 | or/59-65 |
| 67 | 48 not 66 |
| 68 | 21 and 67 |

Databases: Embase; and Embase Classic

| # | Searches |
|----|--|
| 1 | HEALTH ECONOMICS/ |
| 2 | exp ECONOMIC EVALUATION/ |
| 3 | exp HEALTH CARE COST/ |
| 4 | exp FEE/ |
| 5 | BUDGET/ |
| 6 | FUNDING/ |
| 7 | RESOURCE ALLOCATION/ |
| 8 | |
| 9 | budget*.ti,ab. cost*.ti,ab. |
| 10 | (economic* or pharmaco?economic*).ti,ab. |
| 11 | · · · · · · · · · · · · · · · · · · · |
| 12 | (price* or pricing*).ti,ab. |
| 13 | (financ* or fee or fees or expenditure* or saving*).ti,ab. (value adj2 (money or monetary)).ti,ab. |
| 14 | resourc* allocat*.ti,ab. |
| 15 | (fund or funds or funding* or funded).ti,ab. |
| 16 | (ration or rations or rationing* or rationed).ti,ab. |
| 17 | or/1-16 |
| 18 | NEWBORN/ |
| 19 | (neonat\$ or newborn\$ or new-born\$ or baby or babies).ti,ab. |
| 20 | PREMATURITY/ |
| 21 | ((preterm\$ or pre-term\$ or pre-matur\$ or pre-matur\$) adj5 (birth? or born)).ab,ti. |
| 22 | ((preterm\$ or pre-term\$ or pre-matur\$ or pre-matur\$) adj5 (birth: or born)).ab,ti. |
| 23 | (pre#mie? or premie or premies).ti,ab. |
| 24 | exp LOW BIRTH WEIGHT/ |
| 25 | (low adj3 birth adj3 weigh\$ adj5 infan\$).ti,ab. |
| 26 | ((LBW or VLBW) adj5 infan\$).ti,ab. |
| 27 | NEWBORN INTENSIVE CARE/ |
| 28 | NEONATAL INTENSIVE CARE UNIT/ |
| 29 | NICU?.ti.ab. |
| 30 | or/18-29 |
| 31 | PARENTERAL NUTRITION/ |
| 32 | TOTAL PARENTERAL NUTRITION/ |
| 33 | PERIPHERAL PARENTERAL NUTRITION/ |
| 34 | PARENTERAL SOLUTIONS/ |
| 35 | INTRAVENOUS FEEDING/ |
| 36 | INTRAVENOUS DRUG ADMINISTRATION/ |
| 37 | exp INTRAVENOUS CATHETER/ |
| 38 | (parenteral\$ or intravenous\$ or intra-venous\$ or IV or venous\$ or infusion?).ti,ab. |
| 39 | ((peripheral\$ or central\$) adj3 (line? or catheter\$)).ti,ab. |
| 40 | drip?.ti,ab. |
| 41 | or/31-40 |
| 42 | 30 and 41 |
| 43 | limit 42 to english language |
| 44 | letter.pt. or LETTER/ |
| 45 | note.pt. |
| 46 | editorial.pt. |
| 47 | CASE REPORT/ or CASE STUDY/ |
| 48 | (letter or comment*).ti. |
| 49 | or/44-48 |
| 50 | RANDOMIZED CONTROLLED TRIAL/ or random*.ti,ab. |
| | |

Neonatal parenteral nutrition: Supplementary material – Health economic literature DRAFT (September 2019)

| # | Searches |
|----|------------------------------------|
| 51 | 49 not 50 |
| 52 | ANIMAL/ not HUMAN/ |
| 53 | NONHUMAN/ |
| 54 | exp ANIMAL EXPERIMENT/ |
| 55 | exp EXPERIMENTAL ANIMAL/ |
| 56 | ANIMAL MODEL/ |
| 57 | exp RODENT/ |
| 58 | (rat or rats or mouse or mice).ti. |
| 59 | or/51-58 |
| 60 | 43 not 59 |
| 61 | 17 and 60 |

Database: Cochrane Central Register of Controlled Trials

| | se: Cochrane Central Register of Controlled Trials |
|----|---|
| # | Searches |
| 1 | MeSH descriptor: [ECONOMICS] this term only |
| 2 | MeSH descriptor: [VALUE OF LIFE] this term only |
| 3 | MeSH descriptor: [COSTS AND COST ANALYSIS] explode all trees |
| 4 | MeSH descriptor: [ECONOMICS, HOSPITAL] explode all trees |
| 5 | MeSH descriptor: [ECONOMICS, MEDICAL] explode all trees |
| 6 | MeSH descriptor: [RESOURCE ALLOCATION] explode all trees |
| 7 | MeSH descriptor: [ECONOMICS, NURSING] this term only |
| 8 | MeSH descriptor: [ECONOMICS, PHARMACEUTICAL] this term only |
| 9 | MeSH descriptor: [FEES AND CHARGES] explode all trees |
| 10 | MeSH descriptor: [BUDGETS] explode all trees |
| 11 | budget*.ti,ab. |
| 12 | cost*.ti,ab. |
| 13 | (economic* or pharmaco?economic*).ti,ab. |
| 14 | (price* or pricing*).ti,ab. |
| 15 | (financ* or fee or fees or expenditure* or saving*).ti,ab. |
| 16 | (value near/2 (money or monetary)).ti,ab. |
| 17 | resourc* allocat*.ti,ab. |
| 18 | (fund or funds or funding* or funded).ti,ab. |
| 19 | (ration or rations or rationing* or rationed).ti,ab. |
| 20 | ec.fs. |
| 21 | #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 |
| 22 | MeSH descriptor: [INFANT, NEWBORN] this term only |
| 23 | (neonat* or newborn* or new-born* or baby or babies).ti,ab. |
| 24 | MeSH descriptor: [PREMATURE BIRTH] this term only |
| 25 | ((preterm* or pre-term* or prematur* or pre-matur*) near/5 (birth? or born)).ab,ti. |
| 26 | MeSH descriptor: [INFANT, PREMATURE] explode all trees |
| 27 | ((preterm* or pre-term* or prematur* or pre-matur*) near/5 infan*).ti,ab. |
| 28 | (pre#mie? or premie or premies).ti,ab. |
| 29 | MeSH descriptor: [INFANT, LOW BIRTH WEIGHT] explode all trees |
| 30 | (low near/3 birth near/3 weigh* near/5 infan*).ti,ab. |
| 31 | ((LBW or VLBW) near/5 infan*).ti,ab. |
| 32 | MeSH descriptor: [INTENSIVE CARE, NEONATAL] this term only |
| 33 | MeSH descriptor: [INTENSIVE CARE UNITS, NEONATAL] this term only |
| 34 | NICU?.ti,ab. |
| 35 | #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 or #30 or #31 or #32 or #33 or #34 |
| 36 | MeSH descriptor: [PARENTERAL NUTRITION] this term only |
| 37 | MeSH descriptor: [PARENTERAL NUTRITION, TOTAL] this term only |
| 38 | MeSH descriptor: [PARENTERAL NUTRITION SOLUTIONS] this term only |
| 39 | MeSH descriptor: [ADMINISTRATION, INTRAVENOUS] this term only |
| 40 | MeSH descriptor: [INFUSIONS, INTRAVENOUS] this term only |
| 41 | MeSH descriptor: [CATHETERIZATION, CENTRAL VENOUS] this term only |
| 42 | MeSH descriptor: [CATHETERIZATION, PERIPHERAL] explode all trees |
| 43 | (parenteral* or intravenous* or intra-venous* or IV or venous* or infusion?).ti,ab. |
| 44 | ((peripheral* or central*) near/3 (line? or catheter*)).ti,ab. |
| 45 | drip?.ti,ab. |
| 46 | #36 or #37 or #38 or #39 or #40 or #41 or #42 or #43 or #44 or #45 |
| 47 | #21 and #35 and #46 |


Databases: Health Technology Assessment; and NHS Economic Evaluation Database

| | ALGOGO | | | | | | |
|----|---|--|--|--|--|--|--|
| # | Searches | | | | | | |
| 1 | MeSH descriptor: [INFANT, NEWBORN] this term only | | | | | | |
| 2 | (neonat* or newborn* or new-born* or baby or babies).ti,ab. | | | | | | |
| 3 | MeSH descriptor: [PREMATURE BIRTH] this term only | | | | | | |
| 4 | ((preterm* or pre-term* or prematur* or pre-matur*) near/5 (birth? or born)).ab,ti. | | | | | | |
| 5 | MeSH descriptor: [INFANT, PREMATURE] explode all trees | | | | | | |
| 6 | ((preterm* or pre-term* or prematur* or pre-matur*) near/5 infan*).ti,ab. | | | | | | |
| 7 | (pre#mie? or premie or premies).ti,ab. | | | | | | |
| 8 | MeSH descriptor: [INFANT, LOW BIRTH WEIGHT] explode all trees | | | | | | |
| 9 | (low near/3 birth near/3 weigh* near/5 infan*).ti,ab. | | | | | | |
| 10 | ((LBW or VLBW) near/5 infan*).ti,ab. | | | | | | |
| 11 | MeSH descriptor: [INTENSIVE CARE, NEONATAL] this term only | | | | | | |
| 12 | MeSH descriptor: [INTENSIVE CARE UNITS, NEONATAL] this term only | | | | | | |
| 13 | NICU?.ti,ab. | | | | | | |
| 14 | #1 or #2 or #3 or #4 or #5 or #6 or #7 or #8 or #9 or #10 or #11 or #12 or #13 | | | | | | |
| 15 | MeSH descriptor: [PARENTERAL NUTRITION] this term only | | | | | | |
| 16 | MeSH descriptor: [PARENTERAL NUTRITION, TOTAL] this term only | | | | | | |
| 17 | MeSH descriptor: [PARENTERAL NUTRITION SOLUTIONS] this term only | | | | | | |
| 18 | MeSH descriptor: [ADMINISTRATION, INTRAVENOUS] this term only | | | | | | |
| 19 | MeSH descriptor: [INFUSIONS, INTRAVENOUS] this term only | | | | | | |
| 20 | MeSH descriptor: [CATHETERIZATION, CENTRAL VENOUS] this term only | | | | | | |
| 21 | MeSH descriptor: [CATHETERIZATION, PERIPHERAL] explode all trees | | | | | | |
| 22 | (parenteral* or intravenous* or intra-venous* or IV or venous* or infusion?).ti,ab. | | | | | | |
| 23 | ((peripheral* or central*) near/3 (line? or catheter*)).ti,ab. | | | | | | |
| 24 | drip?.ti,ab. | | | | | | |
| 25 | #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 | | | | | | |
| 26 | #14 and #25 | | | | | | |
| | | | | | | | |

Economic study selection

Economic evidence study selection is shown in Figure 1. The number of included and excluded studies for each review question is detailed in Table 1.

Figure 1: Economic study selection for neonatal parenteral nutrition



1 Table 1: Summary of economic study selection

| Tubic | 1. Summary of economic study selection | | | | |
|-------|--|--|----------------------------|----------------------------|--|
| | Chapter | Review questions | Number of included studies | Number of excluded studies | |
| 1.1 | Α | What are the predictors for enteral feeding success? | 0 | 0 | |
| 1.2 | В | For those neonates where parenteral nutrition is required, what is the optimal timeframe for doing this? | 0 | 0 | |
| 1.3 | C1 | What are the most effective relative amounts of nitrogen and non-nitrogen energy (starting and target dose)? | 0 | 0 | |
| 1.4 | C2 | What are the most effective relative amounts of carbohydrates and lipids (starting and target dose)? | 0 | 0 | |
| 2.1 | D | How many kcal/kg/day should be given to preterm and term babies receiving parenteral nutrition? | 0 | 0 | |
| 3.1 | E1 | What is the optimal target dosage for amino acids in preterm and term babies who are receiving parenteral nutrition and neonatal care? | 0 | 0 | |
| 3.2 | E2 | What is the optimal way (starting dose and approach to increment, if employed) to achieve this target dosage for amino acids? | 0 | 0 | |
| 3.3 | F1 | What is the optimal target dosage for carbohydrates in preterm and term babies who are receiving parenteral nutrition and neonatal care? | 0 | 0 | |
| 3.4 | F2 | What is the optimal way (starting dose and approach to increment, if employed) to achieve this target dosage for carbohydrates? | 0 | 0 | |
| 3.5 | G1 | What is the optimal target dosage for lipids in preterm and term babies who are receiving parenteral nutrition and neonatal care? | 0 | 0 | |
| 3.6 | G2 | What is the optimal way (starting dose and approach to increment, if employed) to achieve this target dosage for lipids? | 0 | 0 | |
| 3.7 | Н | What is the clinical effectiveness, efficacy, and safety of lipid formulations from different sources (for example, soya, fish oil, or mixed sources)? | 0 | 0 | |
| 3.8 | I1 | What are the optimal target dosages for calcium and phosphate in preterm and term babies who are receiving parenteral nutrition and neonatal care? | 0 | 0 | |
| 3.9 | 12 | What is the optimal ratio of phosphate to amino acid in preterm and term babies who are receiving parenteral nutrition and neonatal care? | 0 | 0 | |

Neonatal parenteral nutrition: Supplementary material – Health economic literature DRAFT (September 2019)

| | Chapter | Review questions | Number of included studies | Number of excluded studies |
|------|---------|--|----------------------------|----------------------------|
| 3.10 | J | What is the most effective and safe iron supplementation compared to no iron or different dosage/formulations in preterm and term babies who are receiving parenteral nutrition and neonatal care? | 0 | 0 |
| 3.11 | K | How much (if any) intravenous acetate should be provided to preterm and term babies who are receiving parenteral nutrition and neonatal care? | 0 | 0 |
| 3.12 | L | What is the effectiveness, efficacy and safety of standardised parenteral nutrition bags compared with individualised bags? | 3 | 0 |
| 4.1 | M | What overall osmolality, concentration of calcium and glucose/dextrose in parenteral nutrition can determine whether to administer centrally or peripherally? | 0 | 0 |
| 5.1 | N | In babies on parenteral nutrition, what is the optimal frequency of blood sampling for monitoring glucose, calcium, phosphate, potassium and serum triglycerides? | 0 | 0 |
| 6.2 | 0 | What amount of enteral feed (measured in terms of ml/kg/d, or kcal/kg/d, or ratios in relation to PN and enteral feeds) indicates that parenteral nutrition is no longer required? | 0 | 0 |
| 7.1 | P | Are nutrition care/support teams effective in providing parenteral nutrition in preterm and term babies? | 0 | 0 |
| 8.1 | Q | What are the most effective methods of information provision about PN, and what information and support about this do parents/carers perceive as useful? | 0 | 0 |
| 9.1 | R | What are the general principles of neonatal parenteral nutrition? | 0 | 0 |